Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Pulmonary Atresia Diagnostics Treatment Market Share

ID: MRFR//5025-HCR | 100 Pages | Author: Rahul Gotadki| May 2024

Effective market percentage positioning within the Pulmonary Atresia diagnostics and treatment market starts evolving with a deep know-how of the disease panorama and market segmentation. Companies conduct thorough studies to become aware of key segments and tailor their techniques to unique patient needs. Establishing sturdy collaborations with healthcare experts is an essential element. Companies work intently with cardiologists, pediatricians, and other specialists to take advantage of insights, endorsements, and referrals, strengthening their position as trusted partners in Pulmonary Atresia diagnostics and treatment. Staying at the leading edge of diagnostic technologies is crucial. Market leaders invest in superior imaging and diagnostic gear to beautify accuracy in Pulmonary Atresia analysis. Incorporating modern technology contributes to each diagnostic precision and market competitiveness.
Investing in scientific trials and studies is vital for staying ahead within the Pulmonary Atresia market. Companies contribute to clinical advancements by collaborating on study initiatives, showcasing dedication to innovation, and improving remedy effects. Given the essential nature of healthcare, regulatory compliance, and nice warranties are pinnacle priorities. Companies adhere to rigorous requirements to ensure the safety and efficacy of diagnostic and remedy products, building belief among healthcare experts and patients. Companies explore possibilities for worldwide growth within the Pulmonary Atresia market. Adapting merchandise and treatment techniques to meet numerous local requirements and navigating numerous regulatory landscapes contribute to a broader market percentage.
Embracing technological improvements, organizations integrate telemedicine and faraway monitoring answers. This enables ongoing affected person care and complements accessibility, mainly in regions where admission to specialized healthcare may be confined. Establishing affected person guide programs is a key issue of market positioning. Companies offer help packages that provide financial assistance, counseling offerings, and academic sources, contributing to a normal, high-quality affected person experience. Recognizing the economic burden on sufferers, agencies strategize to offer low-cost remedy alternatives. This entails exploring price-effective manufacturing approaches, forming partnerships, and imposing pricing models that stabilize accessibility with sustainability. Leveraging facts for healthcare solutions is gaining prominence. Companies examine affected persons' information to become aware of tendencies, refine treatment protocols, and make a contribution to the development of records-driven healthcare answers, showcasing a dedication to non-stop development.

Pulmonary Atresia Diagnostics and Treatment Market Scenario

The pulmonary atresia diagnostics and treatment market is expected to register a USD 4.89 Billion at a CAGR 5.10% during the forecast period (2023–2030).

Pulmonary atresia is the type of inherited heart defect that a baby is born with. It arises when the pulmonary valve normally located between the right ventricle and the pulmonary artery doesn’t form properly. The valve should have three leaflets which allow the blood to flow forward into the pulmonary artery but prevent it from flowing backward into the right ventricle. In the case of congenital pulmonary atresia patients, the valve either malfunctions or does not form at all. The tissue formed in the place of pulmonary valve does not allow the blood flow into the pulmonary artery. This flaw develops in the first eight weeks of pregnancy and disturbs the flow of blood from the right ventricle to the pulmonary artery leading to the lungs. It can be recognized in a prenatal ultrasound.

The most common symptoms are blue or gray-toned skin, troubled breathing, weakness, sleepiness, and others. Factors such as technological advancements, increasing awareness, lifestyle changes are the major driving factors for the growth of the market. However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restrains for the market include the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the pulmonary atresia diagnostics and treatment market negatively. 


The pulmonary atresia diagnostics and treatment market has been segmented on the basis of type, diagnosis, treatment and end users.

On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect.

On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization.

On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant.

On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European pulmonary atresia diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The pulmonary atresia diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pulmonary atresia diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Global Pulmonary Atresia Diagnostics and Treatment Market Share, by Region, 2017 (%)

Pulmonary Atresia Diagnostics and Treatment Market Share

Source: MRFR Analysis

In the pulmonary atresia diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into medical devices manufacturing. According to the Centers for Disease Control and Prevention, about 40,000 births are affected by congenital heart defects in the US every year.

The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to the Centers for Disease Control and Prevention, congenital heart defects are a foremost cause of birth defect associated with infant illness and deaths. The deaths often occur when the infant is less than 28 days old and hence diagnosis of the defect is utmost important.

Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.

The market in the Middle East & Africa is expected to account for the smallest share of the pulmonary atresia diagnostics and treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.

Market of Pulmonary Atresia Diagnostics and Treatment, by Type

  • Pulmonary atresia with an intact ventricular septum

  • Pulmonary atresia with ventricular septum defect

Market of Pulmonary Atresia Diagnostics and Treatment, by Diagnosis

  • Pulse oximetry

  • Electrocardiogram (ECG)

  • Echocardiogram (cardiac ultrasound)

  • Cardiac MRI

  • Cardiac catheterization

Market of Pulmonary Atresia Diagnostics and Treatment, by Treatment

  • Medication

  • Cardiac catheterization

  • Radiofrequency ablation

  • Balloon valvotomy

  • Balloon atrial septostomy

  • Stent placement

  • Surgery

  • Right ventricular outflow reconstruction

  • Blalock-Taussig Shunt

  • Bi-directional Glenn procedure

  • Fontan procedure

  • Heart transplant

Market of Pulmonary Atresia Diagnostics and Treatment, by End-Users

  • Hospitals

  • Clinics

  • Diagnostic centers

  • Specialty Clinics

  • Research Institutes

  • Others

Market of Pulmonary Atresia Diagnostics and Treatment, by Region

  • Americas

  • North America

  • US

  • Canada

  • South America

  • Europe

  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe

  • Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • Middle East & Africa

  • Middle East

  • Africa

Intended Audience

  • Governmental Agency

  • Educational Organizations

  • Medical Device Manufacturers

  • Research Institutes and Academic Centers

  • Market Research and Consulting

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.